BR9712197A - Formulação farmacêutica líquida aquosa e processos de preparação da mesma, e, de inibição de reabsorção de osso. - Google Patents

Formulação farmacêutica líquida aquosa e processos de preparação da mesma, e, de inibição de reabsorção de osso.

Info

Publication number
BR9712197A
BR9712197A BR9712197-5A BR9712197A BR9712197A BR 9712197 A BR9712197 A BR 9712197A BR 9712197 A BR9712197 A BR 9712197A BR 9712197 A BR9712197 A BR 9712197A
Authority
BR
Brazil
Prior art keywords
processes
pharmaceutical formulation
preparing
liquid pharmaceutical
aqueous liquid
Prior art date
Application number
BR9712197-5A
Other languages
English (en)
Inventor
Maneesh J Nerurkaar
William H Hunke
Drazen Ostovic
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9700541.7A external-priority patent/GB9700541D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BR9712197A publication Critical patent/BR9712197A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMULAçãO FARMACêUTICA LìQUIDA AQUOSA E PROCESSOS DE PREPARAçãO DA MESMA, E, DE INIBIçãO DE REABSORçãO DE OSSO". Uma formulação líquida de ácido alendrónico ou de um sal farmaceuticamente aceitável tem suficiente tampão de modo que o pH da formulação seja 4-7,5, e 15 ml da formulação sejam capazes de aumentar o pH de 50 ml de HC1 0,1 N de um até pelo menos 3 e de preferência 4.
BR9712197-5A 1996-10-04 1997-10-02 Formulação farmacêutica líquida aquosa e processos de preparação da mesma, e, de inibição de reabsorção de osso. BR9712197A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2676596P 1996-10-04 1996-10-04
GBGB9700541.7A GB9700541D0 (en) 1997-01-13 1997-01-13 Liquid alendronate formulation
US3600297P 1997-01-22 1997-01-22
PCT/US1997/015740 WO1998014196A1 (en) 1996-10-04 1997-10-02 Liquid alendronate formulations

Publications (1)

Publication Number Publication Date
BR9712197A true BR9712197A (pt) 1999-08-31

Family

ID=27268667

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712197-5A BR9712197A (pt) 1996-10-04 1997-10-02 Formulação farmacêutica líquida aquosa e processos de preparação da mesma, e, de inibição de reabsorção de osso.

Country Status (20)

Country Link
EP (1) EP1007054A4 (pt)
JP (1) JP2001501222A (pt)
CN (1) CN1238691A (pt)
AU (1) AU723357B2 (pt)
BG (1) BG103306A (pt)
BR (1) BR9712197A (pt)
CA (1) CA2267370A1 (pt)
CZ (1) CZ116999A3 (pt)
EA (1) EA001213B1 (pt)
EE (1) EE03669B1 (pt)
HU (1) HUP0000125A3 (pt)
IL (1) IL129127A0 (pt)
IS (1) IS5012A (pt)
NO (1) NO991569L (pt)
NZ (1) NZ334836A (pt)
PL (1) PL332496A1 (pt)
SK (1) SK42999A3 (pt)
TR (1) TR199900730T2 (pt)
WO (1) WO1998014196A1 (pt)
YU (1) YU17499A (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60111574T2 (de) 2001-01-23 2006-05-11 Gador S.A. Bisphosphonate enthaltende Zusammensetzungen zur Vorbeugung und/oder Heilung von metabolischen Knochenkrankheiten, Verfahren zu ihrer Herstellung und Benutzung dieser Zusammensetzungen
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080286359A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US20080287400A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
CA2622322A1 (en) * 2005-09-16 2007-03-22 Selamine Ltd Bisphosphonate formulation
US7473684B2 (en) 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
JP2010043119A (ja) * 2009-10-16 2010-02-25 Gador Sa 骨の代謝病の予防および／または治療のための組成物、その組成物の調製方法およびその使用
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206209A (en) * 1978-11-02 1980-06-03 Kracauer Paul Sublingual aspirin tablet
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
FR2703590B1 (fr) * 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US5510517A (en) * 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy

Also Published As

Publication number Publication date
IL129127A0 (en) 2000-02-17
CA2267370A1 (en) 1998-04-09
IS5012A (is) 1999-03-26
EE03669B1 (et) 2002-04-15
EE9900113A (et) 1999-10-15
EA001213B1 (ru) 2000-12-25
JP2001501222A (ja) 2001-01-30
PL332496A1 (en) 1999-09-13
HUP0000125A2 (hu) 2000-06-28
BG103306A (en) 2000-01-31
NZ334836A (en) 2000-11-24
TR199900730T2 (xx) 1999-07-21
NO991569D0 (no) 1999-03-30
CZ116999A3 (cs) 1999-09-15
AU723357B2 (en) 2000-08-24
SK42999A3 (en) 2000-01-18
CN1238691A (zh) 1999-12-15
EP1007054A1 (en) 2000-06-14
WO1998014196A1 (en) 1998-04-09
EP1007054A4 (en) 2000-07-19
EA199900352A1 (ru) 1999-08-26
YU17499A (en) 1999-11-22
NO991569L (no) 1999-06-04
AU4644897A (en) 1998-04-24
HUP0000125A3 (en) 2001-04-28

Similar Documents

Publication Publication Date Title
ES2244831T5 (es) Uso de pantenol y/o ácido pantoténico y ácido hialurónico y/o hialuronato para la producción de una composición farmacéutica para aplicación oftalmológica
UA40663C2 (uk) Тверда фармацевтична композиція з регульованим вивільненням лікарського засобу для орального вживання
BR0215240A (pt) Derivados de calcona e seu uso no tratamento de doenças
BR0214757A (pt) Formulações farmacêuticas de derivados de platina
NZ234143A (en) Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
MY130157A (en) Method of use for inhibiting bone loss and lowering serum cholesterol
BG101118A (en) Therapeutical compounds
NO20022264L (no) Farmasoytisk blanding inneholdende tolterodin, samt anvendelse derav
TR199903191T2 (xx) Vorikonazol i�eren ila� form�lasyonlar�.
WO2002072073A3 (en) Pharmaceutical formulation comprising atorvastatin calcium
KR970706830A (ko) 2, 2'-디티오-비스(에탄설포네이트)(디메스나)와 조합된 시스플라틴의 조성물(composition of cisplatin in combination with 2, 2＇-dithio-bis (ethanesulfonate) (dimesna)
TR200003158T2 (tr) Jelleşebilen farmasötik bileşimler
IL109448A0 (en) Risperidone pamoate, its preparation and pharmaceutical compositions containing it
MX9504034A (es) Formas de administracion medicamentosas que contienen acido tioctico, o sales solidas del acido tioctico de liberacion y biodisponibilidad mejoradas.
NO974498L (no) Monomere insulinanalogformuleringer
FI110667B (fi) Menetelmä farmaseuttisen valmisteen valmistamiseksi
DK0501985T3 (da) Uovertrukket farmaceutisk reaktionstablet
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
EP0391002A3 (en) Pharmaceutical compositions containing n-(3,4-dimethoxycinnamoyl) anthranilic acid
EP1291362A4 (en) COMPLEX OF FOLIC ACID AND POLYSACCHARIDES, THE PRODUCTION THEREOF AND THE COMPLEX COMPRISING THE COMPOSITION COMPRISING THE ACTIVE INGREDIENT COMPOSITION
CA2392050A1 (en) Pharmaceutical formulations containing zolmitriptan
TR200101163T2 (tr) Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları
CA2200651A1 (en) Sodium alendronate preparation for local administration
BR9909357A (pt) Solução ou suspensão de mirtazapina em mistura com água, formulação farmacêutica compreendendo mirtazapina, e, uso de mirtazapina
EA199900830A1 (ru) Терапевтическая минераловитаминная ассоциация в форме унитарного жидкого препарата для питья

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.